

UNICHEM

PHARMACEUTICALS (USA), INC.

Dear Valued Customer,

Please be advised that this letter shall provide prompt written notice of a force majeure event caused by the global health emergency related to COVID-19. This crisis is beyond Unichem's reasonable control and is resulting in supply chain interruptions. Unichem is utilizing reasonable commercial efforts to remedy any delay or impact and is utilizing commercially reasonable efforts to eliminate the interruption.

More specifically, last week, the Government of India announced restrictions on the export of 26 finished dose pharmaceutical products, active pharmaceutical ingredients (APIs), and vitamins, in response to the threat posed by COVID-19. This announcement, implemented with immediate effect, will prevent us from obtaining additional inventory of these products for the foreseeable future. Unichem actively markets Metronidazole Tablets, one of the items covered by these restrictions.

In addition, export restrictions and quarantines in areas within China may result in delays of obtaining key source materials (KSMs) and APIs used in the manufacture of other products in Unichem's portfolio, such as Alfuzosin, Allopurinol, Montelukast, and Topiramate.

We will be strictly allocating our on-hand inventory of the above-mentioned products to existing customers until such time that Unichem is completely out of stock or until these restrictions are lifted, at which point Unichem will work carefully to avoid or minimize any potential supply disruption. Your designated account representative will provide you with the allocation quantities in a separate email.

At present, the global response to COVID-19 should not affect other products in our portfolio, but we will follow up with you as soon as we are informed of any potential future disruptions.

Regards,



Scott Delaney
President & Chief Executive Officer
Unichem Pharmaceuticals (USA), Inc.

1 Tower Center Blvd., Suite 2200
East Brunswick, NJ 08816
Tel: 732-253-5954 • Fax: 732-659-6349